Fresenius Infringes Sanofi's Eloxatin Patent: Judge
Sanofi-Aventis US LLC has won summary judgment of infringement against Fresenius Kabi Pharma Ltd., scoring a victory in its bid to keep generic versions of popular colon cancer drug Eloxatin off...To view the full article, register now.
Already a subscriber? Click here to view full article